Stock price performance of EnteroMedics Inc. is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 82.75% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -48.29% . Looking at the past 52 week period, the stock price is down -90.2% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of EnteroMedics Inc. has a negative value of -97.04 compared to overall market performance. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 18.59% and the 50-Day Moving Average is 101.5%.The 200 Day SMA reached 524.1%
EnteroMedics Inc. is having a Relative Strength Index of 51.54 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of EnteroMedics Inc. (NASDAQ:ETRM) rallied by 8.33% during the past week but lost 17.95% on a 4-week basis. The company has outperformed the S&P 500 by 8.2% in the past week but underperformed the index by 18.68% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Jun 6, 2016, Peter M. Delange (SVP, Ops & Bus Dev) purchased 20,000 shares at 0.55 per share price.On May 18, 2016, Dan W Gladney (CEO) purchased 84,745 shares at 0.72 per share price.On Nov 16, 2015, Mark B Knudson (CEO) purchased 310,000 shares at 0.16 per share price.
EnteroMedics Inc. (NASDAQ:ETRM) : On Friday heightened volatility was witnessed in EnteroMedics Inc. (NASDAQ:ETRM) which led to swings in the share price. The stock opened for trading at $7.21 and hit $7.89 on the upside , eventually ending the session at $7.54, with a gain of 4.72% or 0.34 points. The heightened volatility saw the trading volume jump to 1,920,194 shares. The 52-week high of the share price is $132.297354 and the company has a market cap of $30 million. The 52-week low of the share price is at $1.75 .
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.